Relay Medical and Fio Partner with LifeLabs, Canadian Healthcare Leader, to Deploy Fionet Platform for COVID-19 Testing Nationwide

TORONTO, April 14, 2021 (GLOBE NEWSWIRE) -- Relay Medical Corp. (“Relay” or the “Company”) (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2) and Fio Corporation (“Fio”) together through their joint venture company, Fionet Rapid Response Group (“FRR”), announce the execution of an agreement with LifeLabs LP (“LifeLabs”) to deploy the Fionet Platform for COVID-19 rapid testing and real-time tracking across Canada.

LifeLabs is Canada’s largest provider of specialty laboratory testing services, laboratory diagnostic information and digital health connectivity systems, enabling patients and healthcare practitioners to diagnose, treat, monitor, and prevent disease. The company supports 20 million patient visits annually and conducts over 100 million laboratory tests through leading edge technologies and its 6,000 employees.

“COVID-19’s threat to personal and economic well-being across the country created a need for innovation in technology and service. Through this alliance, LifeLabs and FRR are bringing into any community setting the caliber of automated, quality-controlled testing and tracking that previously was available only in centralized lab facilities. FRR expects the Fionet Platform to deliver hundreds of thousands of tests per month through this agreement,” said Dr. Michael Greenberg, CEO of FRR and of Fio Corporation.

“We look forward to partnering with Fionet Rapid Response Group during this critical time in the pandemic. While we see the ongoing deployment of vaccines, the demand for COVID-19 testing remains high. This partnership serves as another big step in our combined efforts to provide safe, accessible, and quality testing for Canadians as we look to re-start our economy as part of our WorkClear program,” said Charles Brown, President and CEO of LifeLabs.

The Fionet Platform enables fast, scalable, quality-controlled testing and real-time automatic digital results for electronic reporting. Each Fionet device processes approximately 60 tests per hour at the point of need. FRR’s business model is a fee for each test processed through its platform.

Under the terms of the agreement, LifeLabs will provide the Fionet Platform in community-based settings at multiple sites across Canada, including airports, pop-up labs, and installations for small businesses. The Fionet Platform is integrated into LifeLabs’ laboratory information system, ensuring seamless interoperation, as well as into LifeLabs’ turnkey, end-to-end COVID-19 rapid diagnostic testing (RDT) program to support Canadians as they return to work.